{"id":"arformoterol-rr-formoterol","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL1363","moleculeType":"Small molecule","molecularWeight":"344.41"},"_fixedAt":"2026-03-30T16:54:24.899557","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Arformoterol is the active R,R-enantiomer of formoterol, a selective beta-2 adrenergic receptor agonist. Upon binding to beta-2 receptors on bronchial smooth muscle, it activates adenylyl cyclase via G-protein coupling, increasing intracellular cAMP levels and leading to smooth muscle relaxation and sustained bronchodilation. As a long-acting formulation, it provides extended therapeutic effect over 12-24 hours.","oneSentence":"Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:32.110Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma (maintenance therapy)"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT00819637","phase":"PHASE4","title":"A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2009-01","conditions":"Acute Asthma","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2003 Aug","pmid":"12970930","title":"[Comparison of RR-formoterol with rac-formoterol in bronchodilating effect on human bronchus].","journal":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences"},{"date":"2002 Sep","pmid":"12236843","title":"Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human.","journal":"British journal of clinical pharmacology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brovana"],"phase":"marketed","status":"active","brandName":"arformoterol (RR formoterol)","genericName":"arformoterol (RR formoterol)","companyName":"Henry Ford Health System","companyId":"henry-ford-health-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}